Sat, June 14, 2025
Fri, June 13, 2025
Thu, June 12, 2025
Wed, June 11, 2025
Tue, June 10, 2025
[ Tue, Jun 10th 2025 ]: rnz
Pacific news in brief for 11 June
Mon, June 9, 2025
[ Mon, Jun 09th 2025 ]: Townhall
Tom Homan Hammers Whiny Newsom
Sun, June 8, 2025
Sat, June 7, 2025
Fri, June 6, 2025

Metsera's drug shows potential in early clinical trial

The article from STAT News dated June 9, 2025, discusses several key developments in the biotech industry. Merck has acquired Eyebiotech for $3 billion to bolster its ophthalmology offerings, while Keros Therapeutics reported positive results from a Phase 2 trial of KER-050 for treating anemia in patients with myelodysplastic syndromes. Metsera, a new company focused on metabolic diseases, launched with $290 million in funding. Axsome Therapeutics received FDA approval for its migraine treatment, AXS-07. The European Medicines Agency (EMA) is set to review the safety of GLP-1 receptor agonists due to concerns over potential side effects. Additionally, the National Institutes of Health (NIH) is facing budget cuts that could impact research funding. Lastly, Amylin Pharmaceuticals is exploring a potential acquisition to expand its portfolio in diabetes and obesity treatments.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/06/09/biotech-news-merck-keros-metsera-axsome-ema-nih-cuts-amylin-the-readout/ ]